345 related articles for article (PubMed ID: 14605866)
1. Greater cell cycle inhibition and cytotoxicity induced by 2-deoxy-D-glucose in tumor cells treated under hypoxic vs aerobic conditions.
Maher JC; Krishan A; Lampidis TJ
Cancer Chemother Pharmacol; 2004 Feb; 53(2):116-22. PubMed ID: 14605866
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of 2-halogen substituted D-glucose analogs in blocking glycolysis and killing "hypoxic tumor cells".
Lampidis TJ; Kurtoglu M; Maher JC; Liu H; Krishan A; Sheft V; Szymanski S; Fokt I; Rudnicki WR; Ginalski K; Lesyng B; Priebe W
Cancer Chemother Pharmacol; 2006 Dec; 58(6):725-34. PubMed ID: 16555088
[TBL] [Abstract][Full Text] [Related]
3. Short-term exposure of multicellular tumor spheroids of a human glioma cell line to the glycolytic inhibitor 2-deoxy-D-glucose is more toxic than continuous exposure.
Khaitan D; Chandna S; Dwarakanath SB
J Cancer Res Ther; 2009 Sep; 5 Suppl 1():S67-73. PubMed ID: 20009299
[TBL] [Abstract][Full Text] [Related]
4. Adducts of mitomycin C and DNA in EMT6 mouse mammary tumor cells: effects of hypoxia and dicumarol on adduct patterns.
Bizanek R; Chowdary D; Arai H; Kasai M; Hughes CS; Sartorelli AC; Rockwell S; Tomasz M
Cancer Res; 1993 Nov; 53(21):5127-34. PubMed ID: 7693331
[TBL] [Abstract][Full Text] [Related]
5. In vitro effects of dichloroacetate and CO2 on hypoxic HeLa cells.
Anderson KM; Jajeh J; Guinan P; Rubenstein M
Anticancer Res; 2009 Nov; 29(11):4579-88. PubMed ID: 20032407
[TBL] [Abstract][Full Text] [Related]
6. [Impact of RNA interference targeting hypoxia-inducible factor-1alpha on chemosensitivity in esophageal squamous cell carcinoma cells under hypoxia].
Wu XA; Sun Y; Fan QX; Wang LX; Wang RL; Zhang L
Zhonghua Yi Xue Za Zhi; 2007 Oct; 87(37):2640-4. PubMed ID: 18162154
[TBL] [Abstract][Full Text] [Related]
7. Hypoxia increases tumor cell sensitivity to glycolytic inhibitors: a strategy for solid tumor therapy (Model C).
Liu H; Savaraj N; Priebe W; Lampidis TJ
Biochem Pharmacol; 2002 Dec; 64(12):1745-51. PubMed ID: 12445863
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms involved in the potentiation of melphalan by the bioreductive compound THNLA-1 in vitro.
Papadopoulou MV; Ji M; Khan SH; Bloomer WD
Oncol Res; 1999; 11(8):345-57. PubMed ID: 10803738
[TBL] [Abstract][Full Text] [Related]
9. Serine/threonine protein phosphatase inhibition enhances the effect of thymidylate synthase inhibition.
Sakoff JA; Howitt IJ; Ackland SP; McCluskey A
Cancer Chemother Pharmacol; 2004 Mar; 53(3):225-32. PubMed ID: 14648018
[TBL] [Abstract][Full Text] [Related]
10. The proliferative response of hela cells to 2-deoxy-D-glucose under hypoxic or anoxic conditions: an analogue for studying some properties of in vivo solid cancers.
Anderson KM; Tsui P; Guinan P; Rubenstein M
Anticancer Res; 2006; 26(6B):4155-62. PubMed ID: 17201127
[TBL] [Abstract][Full Text] [Related]
11. Effect of 2-deoxy-D-glucose on various malignant cell lines in vitro.
Zhang XD; Deslandes E; Villedieu M; Poulain L; Duval M; Gauduchon P; Schwartz L; Icard P
Anticancer Res; 2006; 26(5A):3561-6. PubMed ID: 17094483
[TBL] [Abstract][Full Text] [Related]
12. Effects of reoxygenation on repair of potentially lethal radiation damage in cultured MG-63 osteosarcoma cells.
Iizuka M; Ando K; Aruga T; Furusawa Y; Itsukaichi H; Fukutsu K; Nagasawa H; Moriya H
Radiat Res; 1997 Feb; 147(2):179-84. PubMed ID: 9008210
[TBL] [Abstract][Full Text] [Related]
13. Cytotoxicity, radiosensitization, and chemosensitization of tumor cells by 2-deoxy-D-glucose in vitro.
Dwarakanath BS
J Cancer Res Ther; 2009 Sep; 5 Suppl 1():S27-31. PubMed ID: 20009290
[TBL] [Abstract][Full Text] [Related]
14. Treatment of SW620 cells with Tomudex and oxaliplatin induces changes in 2-deoxy-D-glucose incorporation associated with modifications in glucose transport.
Smith TA; Maisey NR; Titley JC; Jackson LE; Leach MO; Ronen SM
J Nucl Med; 2000 Oct; 41(10):1753-9. PubMed ID: 11038008
[TBL] [Abstract][Full Text] [Related]
15. Radiosensitization by 6-aminonicotinamide and 2-deoxy-D-glucose in human cancer cells.
Varshney R; Dwarakanath B; Jain V
Int J Radiat Biol; 2005 May; 81(5):397-408. PubMed ID: 16076755
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo.
Schwock J; Pham NA; Cao MP; Hedley DW
Cancer Chemother Pharmacol; 2008 Apr; 61(4):669-81. PubMed ID: 17579866
[TBL] [Abstract][Full Text] [Related]
17. Modulation of cellular radiation responses by 2-deoxy-D-glucose and other glycolytic inhibitors: implications for cancer therapy.
Kalia VK; Prabhakara S; Narayanan V
J Cancer Res Ther; 2009 Sep; 5 Suppl 1():S57-60. PubMed ID: 20009297
[TBL] [Abstract][Full Text] [Related]
18. Combining radioimmunotherapy with antihypoxia therapy 2-deoxy-D-glucose results in reduction of therapeutic efficacy.
Dearling JL; Qureshi U; Begent RH; Pedley RB
Clin Cancer Res; 2007 Mar; 13(6):1903-10. PubMed ID: 17363547
[TBL] [Abstract][Full Text] [Related]
19. Differential toxic mechanisms of 2-deoxy-D-glucose versus 2-fluorodeoxy-D-glucose in hypoxic and normoxic tumor cells.
Kurtoglu M; Maher JC; Lampidis TJ
Antioxid Redox Signal; 2007 Sep; 9(9):1383-90. PubMed ID: 17627467
[TBL] [Abstract][Full Text] [Related]
20. Hypoxia-inducible factor-1 confers resistance to the glycolytic inhibitor 2-deoxy-D-glucose.
Maher JC; Wangpaichitr M; Savaraj N; Kurtoglu M; Lampidis TJ
Mol Cancer Ther; 2007 Feb; 6(2):732-41. PubMed ID: 17308069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
